About Us
Vivesto is a Swedish drug development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential.
The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE).
-
Non Regulatory March 13, 2026First dogs dosed in Vivesto’s PK/toxicology study with Cantrixil
-
Regulatory February 27, 2026New number of shares and votes in Vivesto
-
Regulatory January 29, 2026Vivesto carries out a directed share issue to guarantors in connection with the completed rights issue
Year-end Report (in Swedish)
Vivesto published its year-end report for 2025 on February 27, 2026, at 08.00 am CET.